The recent litigation concerning the government’s 340B Rebate Model Pilot Program (the Rebate Program), as further described ...

The American Hospital Association is once again raising concerns about how a major drugmaker handles the government’s 340B ...

The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all ...

Data sovereignty key navigating 340B's future helps healthcare leaders build integrated data systems for compliance and financial resilience in 2026.

The federal government has dropped its appeal of a preliminary injunction blocking implementation of the Department of Health ...

Sagebrush Health Services has filed a lawsuit against Amgen, alleging unlawful termination of discounted drug sales under the ...

The 340B drug pricing plan is meant to help low-income patients. It needs better oversight in this state.

The American Hospital Association is asking the Trump administration to stop Eli Lilly from enacting a new policy as part of ...

The 340B Program has continued to undergo significant upheaval in 2024 that has the potential to bring about impactful changes to how the 340B Program operates moving forward. These developments have ...

The 340B Drug Pricing Program was created to help a targeted group of safety net providers care for low-income and uninsured patients. First enacted as part of the Veterans Healthcare Act of 1992, ...

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

Senator calls on Congress to increase oversight of the 340B Drug Pricing Program by requiring participating providers to complete annual reports on program savings and revenues. If your health system ...